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Background: Gene expression analyses in paired cerebrospinal fluid (CSF) and peripheral blood mononuclear cells
(PBMC) from patients with multiple sclerosis (MS) are restrained by the low RNA amounts from CSF cells and low
expression levels of certain genes. Here, we applied a Taqman-based pre-amplification real-time reverse-transcription
polymerase chain reaction (RT-PCR) (PreAmp RT-PCR) to cDNA from CSF cells and PBMC of MS patients and analyzed
multiple genes related to immune system function and genes expressed by Epstein-Barr virus (EBV), a herpesvirus
showing strong association with MS. Using this enhanced RT-PCR method, we aimed at the following: (1) identifying
gene signatures potentially useful for patient stratification, (2) understanding whether EBV infection is perturbed in CSF
and/or blood, and (3) finding a link between immune and EBV infection status.
Methods: Thirty-one therapy-free patients with relapsing-remitting MS were included in the study. Paired CSF cells and
PBMC were collected and expression of 41 immune-related cellular genes and 7 EBV genes associated with latent or
lytic viral infection were determined by PreAmp RT-PCR. Clinical, radiological, CSF, and gene expression data were
analyzed using univariate and multivariate (cluster analysis, factor analysis) statistical approaches.
Results: Several immune-related genes were differentially expressed between CSF cells and PBMC from the whole MS
cohort. By univariate analysis, no or only minor differences in gene expression were found associated with sex, clinical,
or radiological condition. Cluster analysis on CSF gene expression data grouped patients into three clusters; clusters 1
and 2 differed by expression of genes that are related mainly to innate immunity, irrespective of sex and disease
characteristics. By factor analysis, two factors grouping genes involved in antiviral immunity and immune regulation,
respectively, accurately discriminated cluster 1 and cluster 2 patients. Despite the use of an enhanced RT-PCR method,
EBV transcripts were detected in a minority of patients (5 of 31), with evidence of viral latency activation in CSF cells or
PBMC and of lytic infection in one patient with active disease only.
Conclusions: Analysis of multiple cellular and EBV genes in paired CSF cell and PBMC samples using PreAmp RT-PCR
may yield new information on the complex interplay between biological processes underlying MS and help in
biomarker identification.
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Multiple sclerosis (MS) is the most common chronic in-
flammatory disease of the central nervous system (CNS)
leading to demyelination, axonal damage, and neuronal
loss [1, 2]. The diagnosis of MS relies on clinical symp-
toms, magnetic resonance imaging (MRI) findings, and
laboratory tests, such as detection of oligoclonal bands
in the cerebrospinal fluid (CSF) [3]. MS has a heteroge-
neous and unpredictable clinical course spanning de-
cades; the different rates of progression and the different
responses of patients with relapsing-remitting MS
(RRMS) to therapy remain unexplained.
It is widely accepted that MS pathology is caused by
an inappropriate T-cell-mediated immune response that
is induced in secondary lymphoid organs upon encoun-
ter with still unknown antigens [4]. Leukocyte migration
and activation inside the brain and spinal cord is accom-
panied by persistent intrathecal B-cell activation and
antibody production whose role in MS pathology is not
understood yet [5]. At the cellular level, MS-associated
inflammation is characterized by mild-to-moderate CSF
pleiocytosis, perivascular accumulation of leukocytes
(predominantly lymphocytes and myeloid cells) in the
white matter and in the meninges, organization of
lymphoid-like structures in the subarachnoid space, and
microglia/macrophage activation in the neural paren-
chyma [1, 2]. The relationship between peripheral immune
system activation and CNS inflammation is highlighted by
the therapeutic efficacy of natalizumab, which blocks
leukocyte trafficking in the CNS and markedly reduces
disease activity and leukocyte number, cytokine, and IgG
levels in CSF [6–9].
The identification of sensitive and specific biomarkers
for diagnosis, prognosis, and treatment efficacy of MS is
a relentless effort [10]. At the protein level, CSF bio-
markers for inflammation, like the B-cell attracting che-
mokine C-X-C motif chemokine 13 (CXCL13) and the
extracellular matrix-degrading enzyme metalloprotease-
9 (MMP-9) [11], and for CNS tissue damage, like myelin
basic protein and neurofilament light chain subunit [12],
have been identified. It has been shown that CSF levels
of chitinase-3-like-1 [13, 14] and neurofilament light
[13] chain are significant predictors of MS development
and neurological disability. Several microarray-based
gene expression studies have been carried out in whole
blood or peripheral blood mononuclear cells (PBMC),
aiming at detecting differences in gene signatures between
MS patients and control subjects and between patients
with clinically or radiologically active and inactive disease
[15–20]. However, owing to small sample size, disease het-
erogeneity, and differences in microarray technology and
data analysis, reproducibility across studies has been ex-
tremely limited [21]. Due to the small number of cells col-
lected from the CSF, comprehensive gene expressionstudies in CSF cells are sparse. Compared with healthy
controls or patients with non-inflammatory neurological
diseases, MS patients show increased expression of genes
involved in T-, NK-, and B-cell function in CSF cells
[17, 22–24]. Only a few studies have examined gene ex-
pression in paired CSF cells and PBMC from patients
with MS and non-inflammatory neurological diseases,
confirming poor correlation between intrathecal and
peripheral immune activation [17, 22, 23].
Real-time reverse-transcription polymerase chain reaction
(RT-PCR) incorporating a target gene pre-amplification
(PreAmp) step has the double advantage to improve
detection of low-frequency transcripts and to enable
analysis of a large number of transcripts even with low
amounts of starting RNA [25]. Here, we report the ap-
plication of this enhanced RT-PCR method to paired
CSF cell and PBMC samples from patients with RRMS
and the results of a preliminary analysis on nearly 50
genes, including immune-related genes and genes
expressed by Epstein-Barr virus (EBV). This ubiquitous
DNA herpesvirus establishes a life-long latent infection
and shows strong association with MS [26, 27]. MS risk
is higher after infectious mononucleosis, and immune re-
activity to EBV is increased or deregulated in MS patients
compared to healthy subjects, indicating a disturbance in
virus-host interactions [27–29]. It is debated whether an
active EBV infection in the CNS of MS patients can cause
an immunopathological response [27, 30–36]. Although
EBV DNA load in CSF and peripheral blood does not dif-
fer significantly between MS patients and healthy donors
or patients with other neurological diseases [37–40], some
studies support an association between increased EBV
load in peripheral blood and clinical MS attacks [38, 41,
42]. It has not been established yet whether the study of
EBV gene expression, which defines more precisely the
different phases of viral infection [43], might be a better
strategy to investigate EBV perturbation in MS [38, 44].
Thus, the goal of this study has been to evaluate whether
the combined analysis of immune-related and EBV genes in
CSF cells and PBMC obtained from clinically and radiologic-
ally characterized, therapy-free RRMS patients could provide
novel information on the relationship between immune sta-
tus, EBV infection, and MS disease features. After analysis
of the expression levels of each selected gene according to
sex, clinical, MRI, and CSF findings, all the collected data
have been extensively analyzed using multivariate statistical
methods in the attempt to identify gene expression patterns
representative of underlying immunopathological processes
and potentially useful for patient classification.
Methods
Subjects
Patients were recruited at the MS centers of the University
Hospital San Luigi Gonzaga in Orbassano, University of
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proved by the ethic committees of the three participating
MS centers and of the Istituto Superiore di Sanità, and
carried out according to the Declaration of Helsinki.
Written informed consent was obtained from all study
participants.
Thirty-one patients with RRMS were included in this
study [45, 46]. None of the patients received immunomod-
ulatory or immunosuppressive treatment at the time of
CSF and blood sample collection and had not received
such treatments for at least 12 months. Demographic and
clinical information were derived from medical records
and are summarized in Table 1. MS disease onset was de-
fined as the first episode of focal neurological dysfunction
indicative of MS; relapses were defined as the develop-
ment of new or recurrent neurological symptoms not as-
sociated with fever or infection and lasting for at least
24 h [46]. Patients were categorized on the basis of the
presence of a relapse or a condition of remission at the
time of sampling. The expanded disability status scale
(EDSS) score was calculated on the basis of a complete
neurological examination by a neurologist expert in MS.
All patients were examined by a routine brain MRI
protocol before or after sample collection (median time
interval =26 days; range 1–90 days). The time interval
between sample collection and MRI was significantly
shorter in patients in clinical relapse (median =11 days,
range 1–37 days) than in patients in clinical remission
(median =42 days, range 2–90) (p = 0.0015 by Student’s
t test). MRI scans (T2-weighted and T1-weighted pre- and
post-gadolinium administration, slice thickness 5 or 3 mm)
were obtained in all patients using a standardized scanning
protocol [47] with 1.5 T MR scanners.
Sample collection
All CSF and peripheral blood samples were obtained for
routine diagnostic work-up. CSF and blood from each
patient were always drawn on the same day. CSF sam-
ples were processed according to the BioMS-eu consor-
tium guidelines [48]. A total of 3 to 17 ml of CSF
(median =11 ml) were obtained by lumbar spinal tap
with an atraumatic needle. Within 30 min after lumbar
puncture, CSF samples were centrifuged at 1200 rpm for
10 min at room temperature to separate the cellular
component from cell-free supernatant; the cell pellets
were stored at −80 °C in RNAlater (Qiagen) or RNA was












MS (n = 31)
20/11 (1.8) 33 years
(20–65)
1 (0–4.5) 12 months (0drawn in EDTA tubes, and PBMC were isolated using
Lymphoprep, preserved in RNAlater and frozen at −80 °C.
CSF samples were routinely analyzed for cell counts.
Quantitative (IgG index) and qualitative (oligoclonal
bands) analysis of intrathecal IgG synthesis after lumbar
puncture was performed using standard methods.
Pre-amplification real-time RT-PCR
Total RNA was extracted from CSF cells (median =4.5 ×
104, range 7 × 103–5 × 105) and PBMC (4 × 105) using
the AMBION RNAqueous micro kit (Life Technologies,
Grand Island, NY, USA) according to the manufacturer’s
instructions, including genomic DNA digestion. Total
RNA from PBMC was quantified by Nanodrop 2000
(Thermo Fisher Scientific, Waltham, MA, USA) and
200 ng was reverse transcribed for each sample. Because
of the very low and highly variable RNA yield from CSF
cells, the entire volume (15 μl) of RNA extracted from
each CSF sample was reverse transcribed. Reverse-
transcription (RT) was performed using the high cap-
acity reverse transcription kit with RNase inhibitor
(Life Technologies). The resulting cDNA was diluted
to a final volume of 50 μl and splitted into four 12.5 μl
aliquots. To increase the number of targeted copies,
each cDNA aliquot was amplified for the specific gene
assays by pre-amplification reaction (14 cycles) using
the TaqMan PreAmp Master Mix (Life Technologies)
and pooled gene-specific primers, and the reaction
conditions indicated by the manufacturer. Inventoried
and self-designed TaqMan gene expression assays were
used to study cellular and EBV genes, respectively (see
Additional files 1 and 2). Cellular gene assays were pre-
amplified together with the housekeeping gene GAPDH;
viral gene assays were pre-amplified separately together
with GAPDH and the B-cell-specific genes CD19 and
CD20. The pre-amplification product was diluted 1:5 up
to 250 μl in TE buffer, and 4 μl of this dilution was used as
template for a single real-time PCR analysis. Quantitative
PCR experiments were performed in triplicates with the
same inventoried or self-designed TaqMan assays used in
the pre-amplification step (250 nM probe and 900 nM
each primer), using the 7500 Real-Time PCR System (Life
Technologies) for cellular genes and the StepOne Plus
Real-Time PCR System (Life Technologies) for viral genes.
Thermocycling parameters were 50 °C (2 min), 95 °C
(10 min), followed by 40 cycles of 95 °C (15 s) and 60 °C














.1–144) 12 (38.7) 13 (41.9) 7 (0.5–45) 0.81 (0.43–2.2)
Veroni et al. Journal of Neuroinflammation  (2015) 12:132 Page 4 of 18gene expression analysis are expressed as Ct values (Ct =
threshold cycle of PCR at which the amplified product is
detected). The ΔCt is the difference in Ct values derived
from the gene of interest and the reference gene GAPDH;
the factor 2^-ΔCt is used to express the ratio between the
gene of interest and the internal reference gene. To rule
out cross-contamination of reagents and primers, all RT,
pre-amplification, and real-time PCR experiments in-
cluded a NTC sample, containing all the components of
each reaction except for the template. Considering that
12 μl of pre-amplified cDNA was analyzed for each tran-
script and that the available volume of each pre-amplified
aliquot was 250 μl, we were able to analyze in triplicates
up to 20 transcripts per aliquot.
To check that all amplicons were amplified uniformly
without bias, we performed pre-amplification uniformity
experiments using non-limiting cDNA from a human
non pathological pulmonary hilar lymph node (obtained
from Dr. Egidio Stigliano, Institute of Pathological Anat-
omy, Policlinico A. Gemelli, Rome, Italy), as control for
cellular genes, and from an EBV transformed B-
lymphoblastoid cell line (LCL), as control for EBV genes.
The EBV+ LCL (L5) was generated by infecting 5 × 106
PBMC obtained from a patient with MS with B95.8 EBV
strain in a medium containing cyclosporin A (1 μg/ml,
Calbiochem); the outgrowth of B95.8-infected PBMC
was monitored twice a week, and after 5 weeks post-
infection, the LCL was permanently established. Amplifi-
cation of pre-amplified cDNA from lymph node and
EBV+ LCL was compared with that of non pre-amplified
cDNA. Primer uniformity was calculated by the formula
ΔΔCt = ΔCt (Preamp) −ΔCt (cDNA). A ΔΔCt value
within ±1.5 is considered acceptable, as indicated in the
manufacturer’s instructions. Pre-amplification uniformity
values related to the reference gene GAPDH were very
close to zero for all the investigated gene assays (mean
ΔΔCt values ± SD were 0.33 ± 0.35 and 0.90 ± 0.41 for
EBV and cellular transcripts, respectively), indicating
optimal pre-amplification uniformity. PCR efficiency
by direct and PreAmp real-time PCR was checked for
viral genes and found to be similar (range 0.97–1.08;
optimal efficiency = 100 ± 10 %) over serial dilutions of
EBV+ LCL cDNA (from 100 to 0.1 ng, corresponding
to approximately 10.000 to 1 cells). Importantly, simi-
lar data were obtained for each target gene after pre-
amplification from pooled and single assays.
Statistical analysis
Demographic, clinical, radiological, CSF, and gene expres-
sion data of 31 MS patients were analyzed by univariate
and multivariate statistical techniques. In univariate ana-
lyses, comparisons between groups of patients were car-
ried out by Student’s t test and Mann-Whitney test for
continuous variables, and by Fisher’s exact probability testfor categorical variables. Correlation between variables
was assessed by Spearman’s rank correlation coefficient.
Means and SE, or medians and interquartile ranges, were
used to summarize continuous data, and percentages were
used for categorical variables.
To unravel complex gene interactions that may better
capture pathological processes in MS, the collected gene
expression data were analyzed using two multivariate
statistical techniques: cluster analysis aiming to group
subjects into clusters and factor analysis aiming to define
artificial factors, that is underlying latent variables, ad-
equately describing the correlation structure of the
original variables. Cluster analysis was carried out by
average linkage method with Euclidean similarity
measure. Clustering of patients was visualized by dendro-
gram and the choice of number of groups was based on
Calinski/Harabasz pseudo-F index and Duda/Hart index
stopping rules. Factor analysis was carried out using the
principal factor method. Factor loadings, that is, correla-
tions of the original variables with factors, were used
for interpretation of artificial factors. Scores of subjects
on artificial factors were entered in further analyses.
The influence of demographic, clinical, or radiological
parameters on patient clustering and factor scores was
investigated by univariate analyses. Finally, the discrimin-
ating power of artificial factors to predict patient cluster-
ing was assessed. Classification accuracy was assessed
through receiver operating characteristic (ROC) curve
analysis, by calculating the area under ROC curves (AUC)
and its 95 % confidence interval (CI). These analyses were
carried out separately on immune gene expression data
obtained in CSF and PBMC samples.
The level of confidence was set at 0.05 and statistical
significance was assessed by adopting the Bonferroni
correction for multiple testing. Number of comparisons
considered patient subgroups differing for demographic,
clinical, and radiological characteristics, and resulting
from cluster analysis. For correlation analyses, multipli-
city due to two inflammatory CSF parameters (IgG index
and CSF cell count) was considered. Stata 11 was used
for statistical analyses.
Results
Setup of PreAmp real-time RT-PCR
In preliminary experiments, the TaqMan® PreAmp Master
Mix technique was applied to cDNA obtained from hu-
man lymphoid tissue and an EBV+ lymphoblastoid cell
line (L5), as positive controls for immune-related and
viral genes, respectively. Robust pre-amplification of
multiple-pooled Taqman ABI inventoried gene assays (41
cellular genes listed in Additional file 1) and self-designed
gene assays (7 EBV genes listed in Additional file 2) was
obtained with a mean improvement of 4.6 ± 0.4 cycles
(range 4.1–5.1) (p < 0.0001 compared to the Ct values
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shows the specificity and increased sensitivity of PreAmp
RT-PCR and the lower limits of detection of four of the
seven EBV gene expression assays tested in the EBV+ LCL.
Gene expression in CSF cells and PBMC from RRMS patients
PreAmp real-time RT-PCR was then applied to cDNA
from CSF cells and PBMC collected from 31 therapy-free
RRMS patients. Thirty-one CSF and 29 PBMC samples
were eligible for RNA analysis. The demographic, clinical,
and CSF characteristics of the MS cohort are presented
in Table 1. Twelve patients (38.7 %) experienced a clinical
relapse at the time of CSF and blood sampling, and 13
patients (41.9 %) had gadolinium enhancing lesions on
the brain MRI.
Immune-related gene expression
The selected set of immune-related genes includes the
following: T-lymphocyte (CD4, CD8, forkhead box P3
(FoxP3)), B-lymphocyte (CD19, CD20, CD138, and B-Fig. 1 Improved sensitivity and specificity of PreAmp real-time RT-PCR for
genes (EBNA1, LMP1, LMP2A) and one EBV lytic gene (BZLF1) were investig
negative (EBV−) B lymphoma cell line BJAB, with and without pre-amplific
resulted in an improvement of 4.1 to 5.1 cycles within the threshold Ct fo
were detectable down to 1 and 10 EBV+ LCL cells, respectively; no signal
RT-PCR was applied to cDNA from EBV+ LCL cells that were serially diluted in
and lytic transcripts were one and two EBV+ LCL cells in 1 × 104 EBV− negativcell maturation antigen (BCMA), the receptor for B-cell
activating factor (BAFF) and a proliferation-inducing lig-
and expressed on B-lineage cells), natural killer (NK) cell
(CD56, NK cell p46-related protein (NKp46)), mono-
cyte/macrophage (CD68) and plasmacytoid dendritic cell
(pDC) (blood dendritic cell antigen 2 (BDCA-2))
markers; granzyme B and perforin, the lytic enzymes
mediating T cell/NK cell cytotoxic activity; cytokines of
T-cell and/or NK-cell origin (interferon-γ (IFN-γ), inter-
leukin (IL)-2, IL-4, IL-5, IL-17A) and of predominantly
macrophage/DC origin (tumor necrosis factor (TNF),
IL-1β, IL-6, IL-10, p40 (cytokine subunit shared by IL-12
and IL-23), IL-15); major histocompatibility complex
(MHC) class II, involved in antigen presentation; the
enzyme MMP-9 involved in extracellular matrix and
myelin degradation; the enzyme nicotinamide phos-
phoribosyltransferase (NAMPT) involved in inflammation,
metabolic, and stress responses; COX-2, the enzyme re-
sponsible for prostaglandin synthesis at sites of inflamma-
tion; inducible nitric oxide synthase (iNOS), the enzymeEBV transcript detection. a The expression levels of three EBV latent
ated in serially diluted EBV transformed (EBV+) LCL and in the EBV
ation (PreAmp), using Taqman self-designed gene assays. PreAmp
r low gene expression levels (≤35). EBV latent and lytic transcripts
was detected in EBV− BJAB cells confirming assay specificity. b Pre-Amp
a background of EBV− BJAB cells; the lower limits of detection of latent
e cells, respectively
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C-X-C motif chemokine 10 (CXCL10), an IFN-inducible
chemoattractant for activated T cells and NK cells, and
CXCL13, a B-cell chemoattractant; molecules involved in
type-1 IFN production (interferon regulatory factor 7
(IRF7)) and binding (IFN-α-inducible protein 6 (IFN-αR1))
and induced by type-1 IFN (interferon-stimulated exo-
nuclease gene 20 kDa (ISG20), myxovirus (influenza virus)
resistance protein (MxA), 2′-5′-oligoadenylate synthetase
1 (OAS1), protein kinase R (PKR), IFN-induced protein
with tetratricopeptide repeats (IFIT1), IFN-α-inducible
protein 6 (IFI6), ubiquitin-specific peptidase 18 (Usp18)).
Most of the investigated immune transcripts were detected
in all or the majority (>80 %) of CSF and PBMC samples
(Table 2). A few transcripts, like IL-17A, IL-4, p40,
CXCL13, and iNOS, were detected in a lower percentage
of CSF cell and/or PBMC samples; only IL-5 was always
undetectable (Table 2).
Differences in immune-related gene expression between CSF
cells and PBMC and correlation with inflammatory CSF
parameters
Comparison of gene expression values in paired CSF and
PBMC samples available from 29 RRMS patients re-
vealed significantly higher signals for CD138 and BCMA
(p < 0.0001) in CSF cells and of CD68 (p = 0.0002) in
PBMC (Table 2), mirroring the well-documented enrich-
ment in plasmablasts and the paucity of monocytes/
macrophages in CSF compared to peripheral blood [49].
Other transcripts that were enriched in CSF cells com-
pared to PBMC with very high statistical significance
were CD4, FoxP3, BDCA-2, IFN-γ, IL-10, p40, CXCL13,
IRF7, and Usp18 (Table 2), in part confirming knowledge
of intrathecal immune cell recruitment and cytokine
production acquired in flow cytometry and ELISA
studies [50–55]. Statistically, highly significant enrichment
of granzyme B, MMP-9, IL-4, IL-6, IFIT1, NAMPT, and
COX-2 transcripts was found in PBMC compared to CSF
cells (Table 2).
Using Spearman’s rank correlation analysis, significant
correlations were found between inflammatory CSF pa-
rameters and gene expression levels in CSF cells, but not
PBMC. CSF cell number correlated positively with the B-
cell maturation markers BCMA (r = 0.49, p = 0.005) and
CD138 (r = 0.44, p = 0.013) and negatively with the macro-
phage marker CD68 (r = −0.65, p = 0.0001) and the anti-
inflammatory cytokine IL-10 (r = −0.52, p = 0.003). IgG
index correlated positively with CD20 (r = 0.49, p = 0.005)
and negatively with IL-2 (r = −0.43, p = 0.016). These data
are in line with the results of flow cytometry studies in MS
patients showing that the B-cell/monocyte ratio is the
most variable cell parameter in CSF [49, 55] and that ac-
cumulation of B cells/plasmablasts in the CSF correlates
with inflammatory CSF parameters [49–51].Differences in immune-related gene expression among MS
patients
Data analysis was then carried out using two different
approaches, namely: (1) differences in gene expression
levels between RRMS patients differing for demographic,
clinical, and radiological features from an univariate
point of view; and (2) in a multivariate approach using
cluster and factor analyses. Overall, univariate analysis
revealed no or only a few differentially expressed genes
in both CSF cells and PBMC. Females and clinically remit-
ting MS patients displayed significantly higher expression
of CD4 in CSF cells compared to males and clinically re-
lapsing patients, respectively (Fig. 2a). In PBMC, higher
expression of BDCA-2 and IL-10 genes was associated
with clinical remission and relapse, respectively (Fig. 2b).
Cluster analysis on CSF gene expression data divided
RRMS patients into three clusters including 24, 6, and 1
subject, respectively (dendrogram shown in Fig. 3).
Compared to cluster 1 (n = 24), cluster 2 (n = 6) displayed
significantly higher signals for MHC class II, CD68, the
type-1 IFN-induced gene OAS1, CD4 and indicators of
inflammation and macrophage activation like COX-2,
NAMPT, and IL-1β (Fig. 4). ROC curve analyses
highlighted that, among differentially expressed genes,
MHC class II, CD4, CD68, and OAS1 genes showed the
best discriminatory accuracy for cluster 1 and cluster 2
(AUC >0.90 by ROC curve analysis) (Table 3). Conversely,
cluster 1 and cluster 2 did not differ significantly for
demographic (age, sex), clinical (relapse/remission, EDSS),
radiological (absence/presence of gadolinium enhancing
lesions), or CSF (cell number, IgG index) characteris-
tics. It should however be noted that cluster 2 com-
prises only female patients in clinical remission. It is
also worth mentioning that the only patient in cluster 3
(a male in clinical remission and with inactive MRI) dis-
played the highest levels of CSF transcripts for TNF, IL-
1β, IL-6, IL-17A, MMP-9, and CXCL10 within the study
population (see Fig. 4 for IL-1β gene expression values).
Factor analysis on CSF gene expression values identified
four artificial factors that explained 26, 16, 13, and 10 % of
the variability in the dataset, respectively. Table 4 displays
the genes with the strongest correlation with each factor.
Factor 1 strongly correlated (factor loadings ≥0.60) with
most of the analyzed type-1 IFN-related genes (the
transcription factor IRF7 which is activated upon viral
nucleic acid binding to Toll-like receptor (TLR)-7 and
TLR-9 and regulates type-1 IFN production; the type-1
IFN-stimulated genes MxA, PKR, Usp18, OAS1, IFI6,
and IFIT1, and the type-1 IFN receptor subunit IFN-αR1),
the IFN-induced B-cell growth factor BAFF, IFN-γ, the
cytotoxic T-cell marker CD8 and the inflammatory
markers NAMPT, and COX-2, indicating a strong contri-
bution of innate and adaptive antiviral immunity to this
factor. Although at a lower level (factor loadings ranging
Table 2 Expression of immune-related genes in CSF cells and PBMC from RRMS patients













CSF cells and PBMCb
CD20 100 0.28 (0.05–2.23) 100 0.39 (0.05–9.87) n.s.
CD19 97 0.052 (0–0.18) 100 0.041 (0.007–0.18) n.s.
CD138 94 0.033 (0–0.75) 79 0.00014 (0–0.0016) <0.0001
BCMA 97 0.017 (0–0.15) 97 0.0019 (0–0.019) <0.0001
CD4 100 0.74 (0.30–2.44) 100 0.45 (0.014–3.04) 0.0005
CD8 100 1.22 (0.31–4.93) 100 0.86 (0.04–2.27) 0.012
CD56 94 0.015 (0–0.026) 97 0.012 (0–0.90) n.s.
NKp46 90 0.018 (0–0.083) 100 0.025 (0.002–0.129) n.s.
CD68 100 0.29 (0.007–2.02) 100 0.77 (0.04–6.8) 0.0002
FoxP3 97 0.21 (0–2.42) 100 0.059 (0.00002–0.27) 0.0003
BDCA-2 97 0.057 (0–0.42) 100 0.019 (0.001–0.24) 0.0002
Perforin 100 0.18 (0.03–0.70) 100 0.21 (0.029–7.35) n.s.
Granzyme B 97 0.014 (0–0.058) 100 0.068 (0.003–2.51) <0.0001
MMP-9 84 0.006 (0–0.27) 100 0.19 (0.014–9.87) <0.0001
IFN-γ 94 0.01 (0–0.079) 97 0.004 (0–0.089) 0.0064
TNF 100 0.10 (0.03–1.56) 100 0.064 (0.006–2.1) 0.02
IL-1β 97 0.089 (0–6.4) 100 0.45 (0.019–27.8) 0.02
IL- 2 84 0.0016 (0–0.015) 90 0.0007 (0–0.005) 0.03
IL-4 48 0 (0–0.0004) 69 0.00004 (0–0.0009) 0.004
IL-5 0 0 0 0 –
IL-6 84 0.0017 (0–0.14) 97 0.008 (0–0.16) 0.0015
IL-10 97 0.016 (0–0.22) 100 0.005 (0.0001–0.049) 0.0076
IL-15 87 0.026 (0–0.093) 97 0.02 (0–0.12) n.s.
IL-17A 23 0 (0–0.0003) 41 0 (0–0.004) n.s.
p40 77 0.0006 (0–0.046) 59 0.00001 (0–0.0015) 0.003
CXCL10 81 0.0008 (0–0.033) 93 0.0017 (0–0.43) n.s.
CXCL13 81 0.002 (0–0.043) 66 0.00002 (0–0.0005) <0.0001
IRF7 100 0.10 (0.027–0.64) 100 0.022 (0.001–1.65) 0.0006
ISG20 100 1.46 (0.17–6.32) 100 0.59 (0.06–7.0) 0.018
IFI6 100 0.18 (0.023–1.96) 100 0.10 (0.01–10.0) n.s.
MxA 100 0.67 (0.11–6.20) 100 0.24 (0.046–14.39) 0.046
PKR 100 0.36 (0.058–1.91) 100 0.12 (0.006–1.39) 0.023
OAS1 100 0.05 (0.027–0.44) 100 0.038 (0.018–0.90) n.s.
IFIT1 81 0.0006 (0–0.019) 90 0.001 (0–0.18) 0.0089
Usp18 94 0.008 (0–0.052) 93 0.003 (0–0.26) 0.0025
IFN-αR1 97 0.017 (0–0.053) 97 0.010 (0–0.18) n.s.
BAFF 100 0.041 (0.010–0.21) 100 0.051 (0.014–1.03) 0.01
NAMPT 100 0.086 (0.016–0.72) 100 0.37 (0.02–19.9) 0.001
MHC class II 100 3.40 (0.66–9.13) 100 3.0 (0.18–92.1) n.s.
iNOS 52 0.000007 (0–0.0015) 59 0.000005 (0–0.0004) n.s.
COX-2 94 0.046 (0–0.26) 100 0.22 (0.007–2.15) 0.0008
n.s. not significant
aGene expression values are presented as 2^-ΔCt relative to GAPDH. Data obtained in 31 CSF cell and 29 PBMC samples from 31 RRMS patients are shown
bComparisons between paired CSF cell and PBMC samples (available for 29 patients) were made by Wilcoxon signed-rank test
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Fig. 2 Immune-related genes differentially expressed in CSF cells and PBMC from RRMS patients grouped according to sex and clinical status.
Gene expression levels were measured in CSF cells (a) and PBMC (b) from 31 and 29 RRMS patients, respectively, using PreAmp RT-PCR. The
values obtained were compared between patient groups differing for sex (female/male), clinical (relapse/remission), and MRI status (presence/absence
of gadolinium-enhancing lesions). Differences between groups were evaluated by Mann-Whitney test; only statistically significant differences
(p < 0.0125 to account for multiple comparisons) are shown. The lines inside the boxes represent the median value; boxes extend from the 25th
to the 75th percentile, covering the interquartile range (IQR), and whiskers extend from 25th percentile −1.5 IQR to the 75th percentile +1.5 IQR.







































































































































Fig. 3 Dendrogram of RRMS patients based on immune gene expression in CSF cells. Cluster analysis was carried out on the expression data of
41 immune-related genes obtained in 31 CSF cell samples, by using average linkage method with Euclidean similarity measure
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Fig. 4 Genes with discriminatory power in cluster analysis. Gene expression values for MHC class II, CD4, CD68, OAS-1, COX-2, NAMPT, and IL-1β
in CSF cell samples from RRMS patients clustering into groups 1, 2, and 3 are shown. Significant differences in gene expression between group 1
(n = 24) and group 2 (n = 6) patients were assessed by Mann-Whitney test; p values ≤0.0125 are shown. Each dot represents the gene expression
value obtained in each individual patient; the line marks the median value
Veroni et al. Journal of Neuroinflammation  (2015) 12:132 Page 9 of 18from 0.50 to 0.60), factor 1 was also associated with
BDCA-2, perforin, CD4, FoxP3, MHC class II, IL-1β, and
TNF. Factor 2 strongly correlated with myeloid cell/macro-
phage products (IL-1β, IL-6, CXCL10, TNF, MMP-9) and
IL-17A (factor loadings ≥0.70), and to a lesser extent
(factor loadings ranging from −0.60 to 0.52), with IL-15,
perforin, and NKp46, the latter two genes showing an
inverse association. Factor 3 was mainly associated
with CD20, CD19, ISG20, FoxP3, and p40 (factor load-
ings >0.60), and to a lesser extent with BCMA, CD8,Table 3 Discriminatory power for patient clustering of genes
expressed in CSF cells
Genes AUC (95 % CI)







ROC curve analysis was performed to define the accuracy of genes differentially
expressed in CSF cells to discriminate between cluster 1 and cluster 2 patients;
cluster 3 patient was not considered
AUC area under ROC curve, CI confidence intervaland IFIT1. Factor 4 was mainly associated with CD68, IL-
10, and MHC class II (factor loadings >0.60), and to a
lesser extent, with CD4 (factor loading =0.56), suggesting
that this factor may describe an immune regulatory
response involving IL-10-producing macrophages and T
helper cells. None of the analyzed genes contributed to
more than one factor with a factor loading >0.60.
Factor scores were not associated with sex, clinical, or
MRI status. However, patient scores for factor 1 and fac-
tor 4, but not for factor 2 and factor 3, were significantly
higher in cluster 2 than in cluster 1 patients (Fig. 5) with
a high discriminating power (AUC >0.90 by ROC curve
analysis) (Table 5). These findings suggest enrichment of
pathways involved in antiviral/pro-inflammatory (factor 1)
and counter-regulatory (factor 4) immune responses in
the CSF of cluster 2 patients. A scatter plot visualizing
the relationship between factor 1 and factor 4 scores
highlights the spatial segregation of cluster 1 and clus-
ter 2 and suggests that assignment of patients to either
cluster might depend on the ratio between these two
factors (Fig. 6a). Conversely, neither gender nor clinical
(relapse/remission) or radiological (presence/absence of
gadolinium-enhancing lesions) condition determines
such a net separation of patients (Fig. 6b-d). This finding
reinforces the idea that the gene signatures discriminating
Table 4 Factor loadings on CSF gene expression data


































Factor loadings >0.5 are shown
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that are unrelated to disease characteristics at the time of
sampling.
By applying cluster analysis to PBMC gene expression
data (dendrogram shown in Fig. 7), most MS patients
(n = 28) clustered into a single group confirming no major
differences in gene expression patterns. Only a male pa-
tient undergoing a clinical relapse and with an active MRI
scan clustered separately. Factor analysis on PBMC gene
expression data allowed to identify four factors that
altogether explained 63 % of the variability in the dataset(Table 6). Factor 1 was mainly associated with type 1
IFN-related genes (MxA, Usp18, PKR, IFI6, OAS1,
IRF7, IFIT1), BAFF, and the T-cell chemoattractant
CXCL10, which are also IFN-stimulated genes (factor
loadings >0.85), and to a lesser extent, with IL-15,
ISG20, iNOS, CD68, and granzyme B. Factor 2 was
mainly associated with CD56, NKp46, perforin, IFN-
αR1, MHC class II, NAMPT, CD20, and IL-1β (factor
loadings >0.70), and to a lesser extent, with CXCL13
and IL-2, suggesting coordinated NK-cell, B-cell, and
macrophage activation. ISG20, TNF, CD68, MMP-9,
CD8, and to a lesser extent, IL-17A are associated with
factor 3, while BDCA-2, FoxP3, and COX-2 (negative
factor loading), and to a lesser extent, p40 and IL-2 are
associated with factor 4. None of these four factors are
associated with demographic, clinical, radiological, or CSF
features. However, factor 2 score was markedly higher in
the patient clustering separately (score value =5) than in
the remaining MS cohort (median score value =−0.23,
range −1.0 to +0.24). This finding is discussed more exten-
sively in the next paragraph.
EBV gene expression
To search for a link between the immune-related gene
signatures and/or the patient clusters identified by
multivariate statistical approaches and EBV infection sta-
tus, we then evaluated expression of five EBV latent
(EBV-encoded small RNA 1 (EBER1), EBV nuclear anti-
gen (EBNA)1, EBNA3A, latent membrane protein
(LMP)1, LMP2A) and two EBV lytic (BZLF1, gp350/220)
genes in all the analyzable CSF cell and PBMC samples.
EBV transcripts were detected in only a few samples: 3
of 31 CSF cell samples (9.7 %) and 4 of 29 (13.8 %)
PBMC samples from 5 of 31 patients (16.1 %) (Table 7).
All five EBV+ patients belonged to cluster 1, as defined
by cluster analysis on CSF gene expression data; of these,
three were clinically relapsing/MRI active and two were
clinically remitting/MRI inactive (Table 7). Relative to
GAPDH, the frequency of viral transcripts was hundred-
to thousand-fold lower than that of CD19 and CD20
(pre-amplified in the same cDNA aliquot). It is worth
noting that GAPDH Ct values in the three EBV+ CSF
samples ranged between 17.3 and 18.2, while the median
GAPDH Ct value in the MS cohort was 20.0 (range
14.2–27.7), with values >18.5 being detected in 71 % (22
of 31) of CSF samples (Table 7). This suggests that, des-
pite enrichment of target genes by pre-amplification, low
frequency viral transcripts could be missed in most CSF
samples because of insufficient material.
The pattern of EBV gene expression observed in five
MS patients was highly variable (Table 7). In PBMC
from two female patients, one relapsing/MRI active
(FI01) and one remitting/MRI inactive (TO41), detection
of the untranslated EBV transcript EBER1, in the
Fig. 5 Factor 1 and factor 4 derived from CSF gene expression discriminate patients grouped by cluster analysis. Scores for the four factors defined by
factor analysis on CSF gene expression data are shown for each patient classified into clusters 1, 2, or 3 in cluster analysis. Statistically significant
differences in factor scores between group 1 (n = 24) and group 2 (n = 6) patients were assessed by Mann-Whitney test; p values ≤0.0125 are
shown, n.s. not significant. Each dot represents the score value for that specific factor in each individual patient; the line marks the median value
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latency 0 program. This EBV gene program is expressed
in infected circulating memory B cells and allows the
virus to escape immune surveillance [43]. Of these two
patients, only TO41 also displayed EBER1 in CSF cells
together with the EBV latent gene LMP2A. Expression
of LMP2A in the absence of EBV nuclear antigens sug-
gests latency II or default program [43]. EBV latency ac-
tivation (latency II program) manifesting as expression
of LMP1, another gene encoding a latently expressed
membrane protein, was found also in CSF cells of a re-
lapsing/MRI active female patient (TO32) and in PBMC
of a remitting/MRI inactive female patient (CA07)
(Table 7). LMP1 and LMP2A play an important role in
supporting the survival and differentiation of EBV latently
infected B cells by mimicking CD40 and B cell receptor
stimulation, respectively [56–58]. Only a relapsing/MRI
active male patient (FI13) displayed detectable levels of
EBV genes that are expressed during viral reactivation
(Table 7). BZLF1, which is associated with the immediate
early lytic cycle and plays a key role in the switch from la-
tent to lytic infection, was detected in CSF cells while
gp350/220, which is associated with the late lytic cycle and
encodes a major EBV envelope glycoprotein [43, 59], was
detected in PBMC suggesting virion production (Table 7).Table 5 Discriminatory power for patient clustering of factors
derived from CSF gene expression data
Artificial factors AUC (95 % CI)
Factor 1 0.91 (0.80–1.0)
Factor 2 0.42 (0.06–0.79)
Factor 3 0.45 (0.07–0.83)
Factor 4 0.91 (0.78–1.0)
ROC curve analysis was performed to assess the discriminatory accuracy of
factors derived from CSF gene expression data for cluster 1 and cluster 2
patients; cluster 3 patient was not considered
AUC area under ROC curve, CI confidence intervalIn this patient, profound deregulation of EBV infection in
PBMC was also revealed by the presence of EBNA-1 and
EBNA-3A RNA (latency III or growth program) [43] and
strikingly elevated levels of CD20 RNA (25-fold higher
that the median value in the cohort), suggesting new infec-
tion events and B-cell activation, respectively (Table 7). It
is worth noting that the only patient showing EBV reacti-
vation was the same clustering separately from the rest
of the cohort and displaying the highest factor 2 score
based on immune-related gene expression data in PBMC
(see Fig. 7). This finding provides an explanation for the
strong association of factor 2 with genes encoding NK
cell-related and cytotoxicity markers (CD56, NKp46,
perforin, IFN-αR1), pro-inflammatory molecules (NAMPT,
MHC class II, IL-1β, CXCL13) and, as mentioned above,
the B-cell marker CD20 as an indicator of EBV-driven
B-cell expansion/activation.Discussion
The establishment of a relatively simple procedure to
perform large-scale gene expression studies in both CSF
and peripheral blood is an important step forward to-
wards a better understanding of immunopathological
mechanisms and biomarker identification in MS. Here,
we have explored the reliability and usefulness of Pre-
Amp real-time RT-PCR to analyze expression of 41
immune-related genes and 7 EBV genes expressed dur-
ing viral latent and lytic infection in CSF cells and
PBMC obtained from 31 therapy-free RRMS patients
with relatively short disease duration since diagnosis
(median time =12 months). Due to improved sensitivity,
PreAmp RT-PCR allowed relative quantification of low
level cellular transcripts, such as IL-2, IL-4, IL-6, p40,
IL-15, and IL-17A, which are usually undetectable in
CSF and/or peripheral blood cells from MS patients
using conventional RT-PCR methods. By confirming
well-established differences in immune cell composition
A B
C D
Fig. 6 Factor 1 and factor 4 discriminate patients grouped by cluster analysis but not by sex, clinical, or MRI condition. Scatter plots of factor 1 and factor
4 scores in RRMS patients grouped by cluster analysis on CSF gene expression data (a), sex (b), clinical (c), and MRI (d) condition are shown. Cluster 1 and
cluster 2 patients, but not patients grouped according to the other parameters, distribute in two distinct areas (separated by the straight line)
Veroni et al. Journal of Neuroinflammation  (2015) 12:132 Page 12 of 18and mediators of immune responses between CSF cells
and PBMC and the association of B-cell/plasmablast
enrichment with inflammatory CSF parameters, like
CSF cell counts and IgG index, this preliminary study
indicates that Pre-Amp RT-PCR can provide reliable
information on the abundance and activation status of
different immune cell types in both the innate and
adaptive branch.
Univariate analysis revealed no or only minor differ-
ences in immune-related gene expression between MS
patients stratified by sex, clinical, or MRI status. Higher
expression of CD4 in CSF cells from female and remit-
ting patients suggests a relatively higher frequency of T
helper cells, the predominant population in the CSF,
compared to male and relapsing patients. In PBMC,
higher expression of BDCA-2 during clinical remission
and of IL-10 during clinical relapse may reflect an in-
creased frequency of circulating plasmacytoid DC, the
main source of type-1 IFN, and activation of immuneregulatory/suppressive mechanisms, respectively. To
date, no relevant differences in gene expression have
been reproducibly demonstrated in whole blood cells or
PBMC when comparing MS patients and controls, pa-
tients in clinical relapse and remission, or patients with
different disease courses [15–21]. A higher type-1 IFN
signature has been detected in the blood, specifically in
monocytes [60, 61], of a subset of treatment naïve pa-
tients with RRMS and has been associated with a poor
response to IFN-β [60, 62, 63]. Recently, differences in
PBMC gene expression profiles were detected between
male and female patients with RRMS [44], although re-
sults interpretation is complicated by different treatment
regimens.
Owing to the multivariate dimension, cluster and factor
analyses of immune-related gene expression data yielded
more relevant results, allowing for gene signature-based
subgrouping of patients and interpretation of underlying









































































































Fig. 7 Dendrogram of RRMS patients based on immune gene expression in PBMC. Cluster analysis was carried out on the expression data of 41
immune-related genes obtained in 29 PBMC samples, by using average linkage method with Euclidean similarity measure
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fered between CSF cells and PBMC, confirming poor cor-
relation between intrathecal and systemic immune
responses. Cluster analysis carried out on CSF gene ex-
pression data yielded three clusters of patients. Of these,
cluster 1 and cluster 2 (representing 77 and 19 % of the
study population, respectively) significantly differed by
gene expression but not by sex, clinical condition, disease
activity on MRI, or inflammatory CSF parameters. Specif-
ically, cluster 2 showed relatively higher expression of
genes encoding MHC class II, macrophage (CD68) and T
helper cell (CD4) markers, the type 1 IFN-regulated mol-
ecule OAS1, indicators of inflammation (COX-2,
NAMPT), and the macrophage-derived pro-inflammatory
cytokine IL-1β. By factor analysis, correlated genes were
grouped into artificial factors providing information on
specific biological processes. Of these, two factors poten-
tially mirror different and interacting biological processes
that predominate in the CSF of cluster 2 compared to
cluster 1. Factor 1 strongly associates with genes related
to a type-1 IFN response (IRF7, MxA, PKR, Usp18,
OAS1, IFI6, IFIT1, IFN-αR1, BAFF, BDCA-2), cytotoxic/
Th1 T-cell activation (CD8, IFN-γ), and inflammation
(NAMPT, COX-2), while the main contribution of
CD68, IL-10, MHC class II, and CD4 to factor 4 likely
reflects an inhibitory circuit involving immune regula-
tory cells. This interpretation, along with the finding
that assignment of patients to cluster 1 or cluster 2 de-
pends on the ratio between factor 1 and factor 4, is
consistent with a tight balancing of pro- and anti-
inflammatory immune responses in CSF. Because ROC
analysis showed excellent accuracy of some differen-
tially expressed genes, particularly MHC class II, CD4,CD68, and OAS1, as well as of factor 1 and factor 4, in
classifying cluster 1 and cluster 2 patients, future stud-
ies should ask whether these CSF gene signatures, alone
or in combination, may have a prognostic value or be
useful to predict a therapeutic response. Multivariate
analysis carried out on PBMC gene expression data nei-
ther allowed patient clustering nor revealed any signifi-
cant association of immune-related genes grouped into
artificial factors with demographic, clinical, MRI, or
CSF characteristics.
Despite the use of an enhanced RT-PCR method, EBV
RNA was detected in a minority of CSF cell (10 %) and
PBMC (14 %) samples obtained from RRMS patients, a
finding that is in line with most previous studies assessing
EBV DNA load in MS [37–40]. As we have shown that
EBV gene expression was detectable only in CSF cell sam-
ples with higher RNA content (GAPDH Ct values <19), it
cannot be excluded that low RNA amount remains a
major limiting factor for accurate evaluation of EBV infec-
tion status in CSF. However, it is worth noting that in all
CSF samples (n = 3) and half of the PBMC samples (two
out of four) with detectable viral RNA, EBV gene expres-
sion was indicative of a deregulated infection. Perturbation
of EBV infection was inferred by detection of gene products
that are associated with different phases of viral latency
activation and lytic cycle and are usually not detected in
healthy subjects, even when using highly sensitive PCR
techniques [64, 65].
Higher antibody- and T-cell-mediated immune responses
to EBV in MS patients than in control subjects indicate
that EBV infection is perturbed in MS [27–29]. Low
prevalence of EBV nucleic acids in CSF and peripheral
blood of MS patients and absence of marked
Table 6 Factor loadings on PBMC gene expression data



































Factor loadings >0.5 are shown
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controls [37–40] indicate no persistent or substantial
EBV perturbation in these body fluids. However, a
higher EBV DNA load was found in PBMC of patients
with CIS [66] and during MS clinical exacerbations
when serial blood samples were analyzed [38, 41, 42].
Furthermore, a significantly higher incidence of EBV-
induced B-lymphocyte transformation in MS patients
compared to healthy subjects supports the presence of
higher numbers of circulating EBV latently infected Bcells in MS [67, 68]. In normal conditions, the EBV life
cycle mainly occurs inside the lymphoid tissue, par-
ticularly in mucosa-associated lymphoid tissue, like
tonsils, where EBV reactivation can occur at very low
frequency in plasma cells leading to release of viral
particles; the released virus can infect naïve B cells and
establish latency in memory B cells [43, 69]. Latently
infected memory B cells leaving the lymphoid tissue
and entering the blood circulation are extremely rare
and shut down expression of viral genes and proteins
to avoid detection by cytotoxic T cells, thereby main-
taining a life-long infection [70]. Asymptomatic EBV
reactivation in healthy individuals may lead to an in-
crease in viral DNA load in the blood in the absence of
detectable EBV latent and lytic transcripts, reflecting
viral replication in remote lymphoid tissue [64]. The
presence of EBV latent and lytic transcripts in CSF cells
and/or PBMC from a minority of MS patients described
in this study should be interpreted as perturbance of the
normal EBV life cycle, which may be transient and there-
fore difficult to capture in cells circulating through these
body fluids, particularly in studies with a single sampling
design. The results obtained in autoptic tissue samples,
though still controversial [30–32], suggest that an active
EBV infection in MS could be mainly confined to brain
intraparenchymal perivascular spaces, subarachnoid space
where B cells accumulate and organize into B-follicle-like
structures [30], and/or CNS-draining lymph nodes [71].
Selective enrichment of CD4+ and/or CD8+ T cells
specific for EBV antigens in the CSF of patients with
CIS and definite MS has been demonstrated in several
studies, supporting the idea of a localized T-cell response
to EBV in MS [33, 35, 36].
Due to the low prevalence of EBV RNA+ samples in the
analyzed MS cohort, the putative link between EBV infec-
tion status, cellular gene expression, and MS disease fea-
tures could not be evaluated. However, it is worth noting
that the only patient displaying EBV reactivation in CSF
cells and PBMC was clinically and radiologically active. In
PBMC from this patient, a transcript profile suggestive of
profound deregulation of viral latency (EBNA-1/EBNA-
3A) and virion production (EBER/gp350/220 RNA) was
accompanied by the activation of a cellular transcript pro-
file (CD20, CD56, NKp46, perforin, IFN-αR1, MHC class
II, NAMPT, IL-1β, CXCL13) that is compatible with B-
cell expansion and early induction of a robust innate im-
mune response by EBV reactivation [72]. Productive EBV
infection in the peripheral blood in the presence of a dis-
rupted blood-brain barrier could facilitate entry of viral
particles and/or newly infected B cells into the CNS. It is
intriguing that in CSF cells from the same patient, only
BZLF1 RNA, which is associated with the EBV early lytic
cycle, was detectable in the absence of any comparable
sign of immune arousal. This finding may suggest abortive
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Demographic, clinical, MRI, and CSF data of five RRMS patients with detectable EBV transcripts in CSF cells and/or PBMC are shown together with expression values of individual viral genes, B-cell related genes (CD19,
CD20), and the housekeeping gene GAPDH in the corresponding samples
n.d. not detected












Veroni et al. Journal of Neuroinflammation  (2015) 12:132 Page 16 of 18EBV reactivation and impaired/delayed virus recognition
by the immune system in CSF compared to the peripheral
blood. A longitudinal study with serial PBMC sampling
could help understand whether EBV reactivation recurs in
the peripheral blood of MS patients and is associated with
immune-related gene signatures and disease activity. It is
envisaged that MS patients displaying more frequent EBV
reactivation could benefit more from the treatment with
last generation B-cell depleting antibodies [5] or antiviral
drugs [73, 74].Conclusions
This study has allowed to identify PreAmp RT-PCR as a
reliable method to carry out large-scale gene expression
analyses in paired CSF cell and PBMC samples from MS
patients. The results obtained should be interpreted with
caution due to the small number of patients included in
this study. Investigation of a larger number of immune-
related and viral genes in independent patient cohorts is
warranted to explore further the usefulness of this method
to pinpoint dysimmune processes and alterations in the
EBV-host immune system balance in MS. A prospective
study will help understand whether CSF gene signatures
picked up at diagnosis/early disease stages could be of
prognostic value and aid early treatment decisions.Additional files
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genes and the corresponding Taqman inventoried gene expression
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